ANDA 206437, held by Chartwell Molecular. Acyclovir.
As of Nov 13, 2026, ANDA 206437 (Acyclovir), held by Chartwell Molecular, was first approved by FDA on Jul 31, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Acyclovir5% ยท ointment;topical | Acyclovir | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
